ERBB2 and breast cancer: We have demonstrated that HRGβ1 can partially overcome the inhibitory effects of gefitinib monotherapy on growth and invasion of tamoxifen-resistant MCF-7 breast cancer cells through promotion of erbB3/erbB2 heterodimerization and activation of the PI3K/AKT signalling pathway.